Aspen Neuroscience and Bambusa Therapeutics both debuted on Nasdaq, extending an active IPO stretch for biotechs with early-to-mid clinical or platform-driven pipelines. Aspen’s IPO targets a pivotal test of its Parkinson’s disease cell therapy, while Bambusa’s offering supports bispecific antibody development positioned to address limitations of existing monoclonal antibodies. Bambusa’s IPO raised $169 million, with proceeds intended to fund its bispecific antibody pipeline and related research aimed at overcoming the “therapeutic ceiling” associated with conventional mAbs. The company’s approach emphasizes potential differentiation through its bispecific mechanism. Aspen Neuroscience’s IPO raised $141 million to advance its cell therapy into key near-term clinical evaluation. The pairing of two immunology- and neuro-focused launches highlights investor appetite for specialized modalities and well-defined catalysts. For investors and peers, the dual listings underline how public-market access continues to be driven by technical platforms and near-term de-risking milestones rather than late-stage-only pipelines.